Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether CO-1.01 is safe and effective for treating
metastatic pancreatic cancer that did not respond to gemcitabine.